Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• 16-year follow-up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) trial: primary percutaneous coronary intervention vs. fibrinolysis in ST-segment elevation myocardial infarction1 passage
• A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score1 passage
• Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment1 passage
• Anticoagulation for post-operative atrial fibrillation after isolated coronary artery bypass grafting: a meta-analysis1 passage
• Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis1 passage
• Cardiac evaluation of paediatric athletes25 passages
• Colchicine in acutely decompensated heart failure: the COLICA trial1 passage
• Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial1 passage
• Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis1 passage
• Complete revascularization reduces cardiovascular death in patients with ST-segment elevation myocardial infarction and multivessel disease: systematic review and meta-analysis of randomized clinical trials1 passage
• Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial1 passage
• Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial1 passage
• Diagnostic management of acute pulmonary embolism: a prediction model based on a patient data meta-analysis1 passage
• Direct oral anticoagulants vs warfarin in Asian vs non-Asian patients with atrial fibrillation: a patient-level meta-analysis from COMBINE AF1 passage
• EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic1 passage
• Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial1 passage
• Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial1 passage
• Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials1 passage
• Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial1 passage
• Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis1 passage
• Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial1 passage
• Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction1 passage
• Glycoprotein IIb/IIIa inhibitors in acute myocardial infarction and angiographic microvascular obstruction: the REVERSE-FLOW trial1 passage
• Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial1 passage
• In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial1 passage
• Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-difference trial1 passage
• Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction1 passage
• International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management1 passage
• Lipid lowering for prevention of venous thromboembolism: a network meta-analysis1 passage
• Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis1 passage
• Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial1 passage
• Optimal serum potassium concentrations in heart failure: an individual patient data meta-analysis1 passage
• Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation1 passage
• Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation1 passage
• Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial1 passage
• Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials1 passage
• Pre-treatment bicarbonate levels and decongestion by acetazolamide: the ADVOR trial1 passage
• Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis1 passage
• Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients1 passage
• Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation1 passage
• Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial1 passage
• Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial1 passage
• Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials1 passage
• Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis1 passage
• Sex differences in treatment of familial hypercholesterolaemia: a meta-analysis1 passage
• Stratified treatment of myocardial infarction with non-obstructive coronary arteries: the PROMISE trial1 passage
• Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update1 passage
• The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation1 passage
• Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)1 passage
• Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study1 passage